Recent Contributions

Subscrive to our RSS feed

Screenshot Date Categories Title Author Format
Could you comment on the link between visceral fat, liver fat and related metabolic complications? May 16, 2012 Could you comment on the link between visceral fat, liver fat and related metabolic complications? Marja-Riitta Taskinen, MD, PhD, Professor of Medicine, University of Helsinki, Department of Medicine, Biomedicum, Helsinki, Finland Expert Opinions
Video 1:27 min.
6 MB
What is the contribution of visceral adiposity and ectopic fat as factors driving cardiometabolic risk in patients with type 2 diabetes? May 09, 2012 What is the contribution of visceral adiposity and ectopic fat as factors driving cardiometabolic risk in patients with type 2 diabetes? Luc Van Gaal, MD, PhD, Professor of Medicine, Antwerp University Hospital, Faculty of Medicine, Department of Diabetology, Metabolism & Clinical Nutrition, Antwerp, Belgium Expert Opinions
Video 2:42 min.
13 MB
What are the key findings of your 3-year study on the impact of lifestyle modification in patients with visceral obesity? May 02, 2012 What are the key findings of your 3-year study on the impact of lifestyle modification in patients with visceral obesity? Jean-Pierre Després, PhD, FAHA, FIAS, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:43 min.
8 MB
Cardiovascular imaging, metabolic risk factors and atherogenesis: a discussion with Stephen Nicholls April 26, 2012 Cardiovascular imaging, metabolic risk factors and atherogenesis: a discussion with Stephen Nicholls The International Chair on Cardiometabolic Risk Webcasts
Video 17:11 min.
81 MB
Are abdominal obesity and type 2 diabetes a concern for health authorities in Brazil? April 25, 2012 Are abdominal obesity and type 2 diabetes a concern for health authorities in Brazil? Walmir Coutinho, MD, Professor of Endocrinology, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Brazil Expert Opinions
Video 0:56 min.
4 MB
What is the role of the new iPad application developed by the Chair as a new tool for health professionnals? April 19, 2012 What is the role of the new iPad application developed by the Chair as a new tool for health professionnals? Peter Libby, MD, Chief, Cardiovascular Medicine, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, USA Expert Opinions
Video 1:54 min.
9 MB
Could you comment on your views regarding the relative contributions of physical activity and dietary habits in the prevention of type 2 diabetes? April 11, 2012 Could you comment on your views regarding the relative contributions of physical activity and dietary habits in the prevention of type 2 diabetes? Nicholas J. Wareham, MB, PhD, Director, MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK Expert Opinions
Video 0:53 min.
4 MB
What are the key findings of the Dallas Heart Study? April 04, 2012 What are the key findings of the Dallas Heart Study? Gloria Lena Vega, PhD, The Metabolic Unit, Lipid, and Diabetes Clinics of the Veterans Affairs North Health Care System, Dallas, TX, USA Expert Opinions
Video 1:02 min.
5 MB
Is it possible that the subgroup of individuals with features of the metabolic syndrome may be particularly vulnerable in developing type 2 diabetes when exposed to an overconsumption of sugar-sweetened beverages? March 28, 2012 Is it possible that the subgroup of individuals with features of the metabolic syndrome may be particularly vulnerable in developing type 2 diabetes when exposed to an overconsumption of sugar-sweetened beverages? Frank Hu, MD, PhD, Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, MA, USA Expert Opinions
Video 1:31 min.
7 MB
Do you think that the morphology of  atherosclerotic plaque is distinct in patients with type 2 diabetes versus any other type of patients with cardiovascular disease and why? March 21, 2012 Do you think that the morphology of atherosclerotic plaque is distinct in patients with type 2 diabetes versus any other type of patients with cardiovascular disease and why? Darren McGuire, MD, MHSC, Division of Cardiology and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA Expert Opinions
Video 0:52 min.
4 MB
Are there any data on physical activity habits in Mexico? March 14, 2012 Are there any data on physical activity habits in Mexico? Carlos A. Aguilar-Salinas, MD, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubiran (INCMNSZ), Mexico City, Mexico Expert Opinions
Video 1:06 min.
5 MB
Could you discuss and elaborate on the solutions currently considered by various countries to deal with the overconsumption of sugar-sweetened beverages? March 07, 2012 Could you discuss and elaborate on the solutions currently considered by various countries to deal with the overconsumption of sugar-sweetened beverages? Barry Popkin, PhD, Department of Nutrition, School of Public Health and Medicine Department of Economics, The University of North Carolina at Chapel Hill, NC, USA Expert Opinions
Video 2:57 min.
15 MB
Are there ethnic differences in the relationship between total adiposity and visceral adiposity and liver fat? February 29, 2012 Are there ethnic differences in the relationship between total adiposity and visceral adiposity and liver fat? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 0:51 min.
3 MB
Is raising HDL cholesterol concentration by pharmacotherapy a relevant target among individuals with abdominal obesity and low HDL cholesterol? February 22, 2012 Is raising HDL cholesterol concentration by pharmacotherapy a relevant target among individuals with abdominal obesity and low HDL cholesterol? H. Bryan Brewer, Jr., MD, Director, Washington Cardiovascular Associates, Senior Research Consultant, Cardiovascular Research Institute, Washington Hospital Center, Washington, D.C., USA Expert Opinions
Video 1:03 min.
4 MB
Statin therapy has overwhelming benefits to prevent cardiovascular disease. What about valvular disease? February 15, 2012 Statin therapy has overwhelming benefits to prevent cardiovascular disease. What about valvular disease? Philippe Pibarot, DVM, PhD, FAHA, FACC, FASE, Department of Medicine, Université Laval, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 2:05 min.
11 MB